Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR research to practice (R2P) project

Authors

Paul L. Hess, University of Colorado School of Medicine, Denver, CO
Kevin Kennedy, Mid-America Heart Institute, Kansas City, MO
Michael Cowherd, University of Colorado School of Medicine, Denver, CO
Salim S. Virani, Baylor College of Medicine, Houston, TXFollow
Frederick A. Masoudi, University of Colorado School of Medicine, Denver, CO
Ann Marie Navar, Duke Clinical Research Institute, Durham, NC
Robert W. Yeh, Beth Israel Deaconess Medical Center, Boston, MA
P Michael Ho, University of Colorado School of Medicine, Denver, CO
Thomas M. Maddox, Washington University School of Medicine, St Louis, MO

Document Type

Article

Department

Cardiology

Comments

Abstract, issue is not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

American Heart Journal

Recommended Citation

Hess, P. L., Kennedy, K., Cowherd, M., Virani, S. S., Masoudi, F. A., Navar, A. M., Yeh, R. W., Ho, P. M., Maddox, T. M. (2018). Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR research to practice (R2P) project. American Heart Journal, 195, 151-152.
Available at: https://ecommons.aku.edu/provost_office/394